Physician profile
Gilbert D Ortega
NPI 1003349242
$29,783.65
in general payments reported to CMS, 2019-2025
40 companies · $21K in 2025
The $21K reported for 2025 was more than what 94% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $1,208 · 2023: $3,145 · 2024: $4,505 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $13K · Consulting Fee: $1,485 · Travel and Lodging: $799 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,200.00 |
| Food and Beverage | $12,773.53 |
| Consulting Fee | $1,484.85 |
| Travel and Lodging | $799.17 |
| Education | $192.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $18,012.80 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $2,427.52 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,591.54 | 2022-2025 | Cuvitru, Hyqvia, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $1,569.41 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $970.45 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $499.23 | 2022-2025 | Xembify |
| Amgen INC. | $467.78 | 2022-2025 | Tezspire |
| Csl Behring | $397.47 | 2022-2025 | Hizentra, Haegarda |
| Pfizer INC. | $361.45 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $357.49 | 2022-2025 | |
| Optinose US, INC. | $356.93 | 2022-2025 | |
| Biocryst US Sales Co., LLC | $343.34 | 2022-2025 | Orladeyo |
| Octapharma USA, INC. | $330.87 | 2024 | Panzyga |
| Leo Pharma INC. | $274.14 | 2022-2025 | Adbry, Anzupgo |
| Genentech USA, INC. | $202.61 | 2022-2025 | Xolair |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $197.99 | 2025 | Nemluvio |
| Ars Pharmaceuticals Operations, INC. | $186.10 | 2025 | Neffy |
| Kaleo, INC. | $144.97 | 2022-2024 | Auvi-Q |
| Gc Biopharma USA, INC. | $116.42 | 2024-2025 | Alyglo, Alyglo |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Pharming Healthcare, INC. | $94.43 | 2022-2024 | Ruconest |
| Blueprint Medicines Corporation | $78.67 | 2023-2025 | Ayvakit |
| Baxter Healthcare | $75.44 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Incyte Corporation | $71.80 | 2022-2025 | Opzelura |
| Bio Products Laboratory USA, INC. | $64.76 | 2022-2023 | Coagadex, Gammaplex |
| Lilly USA, LLC | $62.62 | 2025 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $50.52 | 2025 | Dawnzera |
| Viatris Specialty LLC | $49.29 | 2025 | Yupelri |
| Abbvie INC. | $46.29 | 2023-2024 | |
| Adma Biomanufacturing LLC | $44.29 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $40.21 | 2022 | |
| Orthofix Medical, INC. | $37.50 | 2025 | Physio-Stim |
| Fresenius Kabi USA, LLC | $31.08 | 2023 | |
| Djo, LLC | $24.99 | 2024 | Cmf |
| Medtronic, INC. | $19.53 | 2024 | Propel |
| Depuy Synthes Sales INC. | $18.91 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $17.90 | 2024 | |
| Phadia US INC. | $16.80 | 2023 | Immunocap |
| Covis Pharma Gmbh | $15.86 | 2022 | |
| Smith+Nephew, INC. | $14.26 | 2023 | Pico 14 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Ortega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.